Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma

JAMA Network Open
Melanie D WhittingtonJonathan D Campbell

Abstract

Axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, represents a new and potentially curative treatment option for B-cell lymphoma. It is expected to have long-term survival benefits; however, long-term survival data are limited. To estimate the long-term survival and cost-effectiveness of axicabtagene ciloleucel for treatment of relapsed or refractory B-cell lymphoma. Economic evaluation study using a survival analysis that digitized and extrapolated survival curves published in the ZUMA-1 trial (Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma), which enrolled patients between November 2015 and September 2016 and had a maximum follow-up of 24 months. Five different survival models (standard parametric, flexible parametric, 2 mixture cure models, and a flexible parametric mixture model) were used to extrapolate the survival curves to a lifetime horizon from January through June 2018. A cost-effectiveness analysis, from both a trial-based and lifetime horizon, was also conducted to inform the value of this novel therapy. The model was based on data from 111 patients with B-cell lymphoma who were enrolled in the ZUMA-1 trial. One-time administration of axicabtagene ciloleu...Continue Reading

References

Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M VoseUNKNOWN Autologous Blood and Marrow Transplant Registry Lymphoma Working Committee
Sep 10, 2005·Blood·Lindsay M MortonMartha S Linet
Jun 8, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Megan OthusJohn J Crowley
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Andrew H BriggsUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Mar 24, 2016·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Christopher JacksonLinda Sharples
Dec 12, 2017·The New England Journal of Medicine·Sattva S NeelapuWilliam Y Go

❮ Previous
Next ❯

Citations

Jun 4, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonathan D Campbell, Melanie D Whittington
Oct 19, 2019·Expert Review of Pharmacoeconomics & Outcomes Research·R Andrew HarkinsChristopher R Flowers
Dec 6, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Melanie D WhittingtonJonathan D Campbell
Feb 15, 2020·Journal of Comparative Effectiveness Research·James R BaumgardnerDarius N Lakdawalla
Mar 20, 2020·Acta Oncologica·Tarec Christoffer El-GalalyDiego Villa
Jun 1, 2020·Bone Marrow Transplantation·Salvatore FiorenzaJoshua A Roth
Oct 9, 2020·Journal of Comparative Effectiveness Research·Keith A BettsAnthony S Masaquel
Nov 27, 2020·Drug Discovery Today·Eline van OverbeekeSteven Simoens
Nov 26, 2020·Archives of Pathology & Laboratory Medicine·Allison M Cushman-VokounSophia Yohe
Jun 6, 2021·Current Hematologic Malignancy Reports·Praveen Ramakrishnan GeethakumariAnkit Kansagra
Jun 17, 2021·British Journal of Haematology·Ameet PatelBhagirathbhai Dholaria
Aug 24, 2020·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Megan OthusScott Ramsey
Oct 7, 2021·CA: a Cancer Journal for Clinicians·Alexander Shimabukuro-VornhagenMichael von Bergwelt-Baildon
Jan 25, 2022·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Hidetoshi ShibaharaTakashi Fukuda

❮ Previous
Next ❯

Methods Mentioned

BETA
leukapheresis

Software Mentioned

CAR
Excel
R

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.